Holding(s) in Company

RNS Number : 9095J

Oxford Biomedica PLC

18 June 2014

 



For filings with the FCA include the annex
For filings with issuer exclude the annex
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi
1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii				Oxford BioMedica plc
2 Reason for the notification (please tick the appropriate box or boxes):
An acquisition or disposal of voting rights					√
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments
An event changing the breakdown of voting rights
Other (please specify):	CHANGE TO THE NUMBER OF VOTING RIGHTS IN ISSUE, FOLLOWING THE RECENT PLACING AND OPEN OFFER				√
3. Full name of person(s) subject to the notification obligation: iii		Aviva plc & its subsidiaries
4. Full name of shareholder(s)  (if different from 3.):iv		Registered Holder: BNY Norwich Union Nominees Limited    5,784,937* Chase (GA Group) Nominees Limited    190,538,969*             * denotes direct interest    Chase (GA Group) Nominees Limited      16,452,188 Chase Nominees Limited                               6,676,094 Vidacos Nominees Limited                          20,547,812
5. Date of the transaction and date on which the threshold is crossed or reached: v		17 June 2014
6. Date on which issuer notified:		18 June 2014
7. Threshold(s) that is/are crossed or reached: vi, vii		0% to 7% Change at Direct Interest Level and 0% to >5% Change at Combined Interest Level

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type of shares if possible using the ISIN CODE

Situation previous to the triggering transaction

Resulting situation after the triggering transaction

Number of Shares

Number of Voting Rights

Number of shares

Number of voting rights

% of  voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

Ordinary Shares GB00066458157

Nil Held

Nil Held

240,000,000

196,323,906

43,676,094

7.87%

1.75%

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial instrument

Expiration date xiii

Exercise/ Conversion Period xiv

Number of voting rights that may be acquired if the instrument is exercised/ converted.

% of voting rights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financial instrument

Exercise price

Expiration date xvii

Exercise/ Conversion period xviii

Number of voting rights instrument refers to

% of voting rights xix, xx

Nominal

Delta

Total (A+B+C)
Number of voting rights	Percentage of voting rights
240,000,000	9.62%

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi
The voting rights are managed and controlled by Aviva Investors Global Services Limited, with the following chain of controlled undertakings:- Aviva Investors Global Services Limited: ·      Aviva plc (Parent Company) ·      Aviva Group Holdings Limited (wholly owned subsidiary of Aviva plc) ·      Aviva Investors Holdings Limited (wholly owned subsidiary of Aviva Group Holdings Limited) ·      Aviva Investors Global Services Limited (wholly owned subsidiary of Aviva Investors Holdings Limited)
Proxy Voting:
10. Name of the proxy holder:		See Section 4
11. Number of voting rights proxy holder will cease to hold:
12. Date on which proxy holder will cease to hold voting rights:
13. Additional information:	Figures are based on on a revised total number of voting rights of 2,494,584,919 as per the Company's Results of Firm Fundraising and Open Offer Announcement of 16 June 2014.
14. Contact name:	Tim Watts, Oxford BioMedica PLC
15. Contact telephone number:	01865 783000

 

END

 

 

HOLUWOWRSVANARR